로딩 중…
지수 로딩 중…
Janux Therapeutics, Inc.
JANX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$15.32+0.99%
2026-08-03
Financials
Valuation Metrics
Janux Therapeutics, Inc.'s Market Cap is $934M. At end of 2025 it was $855M. Ranked #2524 of 3,111 in US market (top 81%), #1044 of 1,445 on NASDAQ (top 72%), #194 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 72%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $934M | US#2,524/3,111 Sec#194/269 |
| Revenue | $22M | US#2,906/3,111 Sec#172/269 |
| Net Income | $-114M | US—/3,111 Sec—/269 |
| Total Assets | $1.03B | US#2,443/3,111 Sec#99/269 |
| Net Assets | $942M | US#1,826/3,111 Sec#67/269 |
| Value | ||
| P/B | 0.99x | US#347/3,111 Sec#16/269 |
| P/S | 43.23x | US#2,876/3,111 Sec#166/269 |
| FCF Yield | -8.40% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -12.16% | US#2,445/3,111 Sec#92/269 |
| ROA | -11.13% | US#2,668/3,111 Sec#106/269 |
| Op. Margin | -726.34% | US#2,917/3,111 Sec#174/269 |
| Revenue Growth | -5.55% | US#2,554/3,111 Sec#139/269 |
| Financial Health | ||
| Debt Ratio | 9.21% | US#98/3,111 Sec#43/269 |
| Total Debt | $22M | US#2,716/3,111 Sec#178/269 |
| FCF | $-78M | US#2,547/3,111 Sec#133/269 |
| Cash | $52M | US#2,578/3,111 Sec#228/269 |
| Current Ratio | 17.01x | US#144/3,111 Sec#45/269 |
| Performance | ||
| 1Y Return | -34.97% | US#2,824/3,111 Sec#235/269 |
| 1M Return | -1.42% | US#1,053/3,111 Sec#71/269 |
| From 52W High | -56.65% | US#2,868/3,111 Sec#232/269 |
| 1Y MDD | -64.94% | US#2,830/3,111 Sec#233/269 |
| Trading | ||
| Volume | 540,310 shares | US#2,026/3,111 Sec#203/269 |
| Trading Value | $8M | US#2,440/3,111 Sec#199/269 |
| Per Share | ||
| EPS | $-1.83 | US—/3,111 Sec—/269 |
| BPS | $15.44 | US#1,460/3,111 Sec#44/269 |